BPM
LGND icon

Bowling Portfolio Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bowling Portfolio Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,090
Closed -$1.05M – 355
2018
Q2 		$1.05M Buy
8,090
+2,964
+58% +$331K 0.15% 229
2018
Q1 		$528K Sell
5,126
-202
-4% -$20K 0.07% 291
2017
Q4 		$455K Buy
+5,328
New +$462K 0.06% 309

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bowling Portfolio Management's LGND Position: Q3 2018 in Review

Bowling Portfolio Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 8,090 shares — an estimated $1.05M sold.

Bowling Portfolio Management first reported a position in LGND in Q4 2017 and held it in 3 quarters. The position peaked at $1.05M in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

  • Bowling Portfolio Management reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Bowling Portfolio Management sold 8,090 Ligand Pharmaceuticals shares in Q3 2018, an estimated $1.05M.
  • Bowling Portfolio Management first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Bowling Portfolio Management's Ligand Pharmaceuticals position peaked at $1.05M in Q2 2018.
  • 385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Bowling Portfolio Management's 13F filing for Q3 2018, filed 18 Oct 2018.